ASTHAstrana Health, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -85% · now 23% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ASTH take a bad year?
Astrana Health, Inc. carries $536M of net debt at 3.34× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 3.34×
Net debt / EBITDA · 0.73× a year ago · the load is going up
- Altman Z-score
- 2.79
Altman Z-score · grey zone, between 1.8 and 3
- Interest cover
- 1.49×
Interest cover · operating profit barely covers the interest bill
Details›
- Total debtQ2 2026
- $936M
- Cash and short-term investments
- $401M
- Net debt
- $536M
- EBITDA, trailing twelve months
- $160M
- Operating profit, trailing twelve months
- $100M
- Debt / equity
- 1.13×
- Total debt / EBITDA
- 5.84×
- Annualised volatilitytwo years of daily moves
- 66%
- Worst drawdown on file
- −85%
- Below its 52-week high
- 23%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.